These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 26938871

  • 1. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T, Hida T, Yatabe Y.
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S, Hayashi H, Okamoto K, Fujiwara K, Hasegawa Y, Kaneda H, Tanaka K, Takeda M, Nakagawa K.
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [Abstract] [Full Text] [Related]

  • 4. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M, Altavilla G, Rosell R.
    Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
    [Abstract] [Full Text] [Related]

  • 5. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 6. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y, Yamamoto N, Masters ET, Kikkawa H, Mardekian J, Wiltshire R, Togo K, Ohe Y.
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [Abstract] [Full Text] [Related]

  • 7. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [Abstract] [Full Text] [Related]

  • 8. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
    Clin Cancer Res; 2014 Nov 15; 20(22):5686-96. PubMed ID: 25228534
    [Abstract] [Full Text] [Related]

  • 9. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.
    J Thorac Oncol; 2015 Feb 15; 10(2):232-6. PubMed ID: 25526238
    [Abstract] [Full Text] [Related]

  • 10. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 15; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 11. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 12. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov 01; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 13. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
    Zhu V, Ou SH.
    Expert Opin Drug Saf; 2017 Apr 01; 16(4):509-514. PubMed ID: 28276856
    [Abstract] [Full Text] [Related]

  • 14. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K.
    Drugs; 2015 Jan 01; 75(1):75-82. PubMed ID: 25428710
    [Abstract] [Full Text] [Related]

  • 15. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
    Asao T, Fujiwara Y, Itahashi K, Kitahara S, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Takahashi K, Ohe Y.
    Clin Lung Cancer; 2017 Jul 01; 18(4):e251-e258. PubMed ID: 28065466
    [Abstract] [Full Text] [Related]

  • 16. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ, Miller VA.
    J Thorac Oncol; 2014 Dec 01; 9(12):1821-5. PubMed ID: 25393796
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N.
    Cancer Chemother Pharmacol; 2016 Mar 01; 77(3):623-8. PubMed ID: 26849637
    [Abstract] [Full Text] [Related]

  • 18. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak-Tapp C, Casey C, He J, Ali SM, Klempner SJ, Miller VA.
    J Thorac Oncol; 2014 Apr 01; 9(4):549-53. PubMed ID: 24736079
    [Abstract] [Full Text] [Related]

  • 19. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N.
    J Thorac Oncol; 2017 Feb 01; 12(2):390-396. PubMed ID: 27498387
    [Abstract] [Full Text] [Related]

  • 20. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V, Pérol M.
    Future Oncol; 2017 Feb 01; 13(4):321-335. PubMed ID: 27780368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.